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In light of the possible adverse effects of radiation on hearing, we conducted a study to
evaluate the long-term sensorineural hearing status following radiotherapy (RT) in patients
suffering from nasopharyngeal carcinoma. Audiologic examinations were performed at
regular intervals before and after RT. We also analyzed the effects of age, chemotherapy,
pre-RT hearing status, and post-RT otitis media with effusion (OME) on post-RT hearing
change. A total of 150 patients (261 ears) were enrolled in this study and followed up for
a mean of 43.8 months. After RT, 8.9–28.8% of ears had at least a 10 dB loss in bone conduction
threshold at speech frequency, which was defined as an average of hearing threshold at
0.5 kHz, 1 kHz, and 2 kHz, while the percentage was 18–34.2% at 4 kHz. Patient age was
related to these changes at speech frequency, and the presence of post-RT OME was related
to significant loss at both speech frequency and 4 kHz. Pre-RT hearing status and
chemotherapy did not influence hearing change. To sum up, sensorineural hearing loss began
as early as after completion of RT. Early changes may be transient, but the effect of radiation
on hearing tended to be chronic and progressive.
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Although many protocols have evolved for the treat-
ment of nasopharyngeal carcinoma (NPC), radio-
therapy (RT) remains the main modality. Inner ear
damage as a result of radiation has been recognized in
animal and human studies [1,2]. Radiation doses de-
livered to the nasopharynx to treat NPC usually ex-
ceed 60 Gy. Moreover, the auditory apparatus is inevi-
tably included in the treatment field, and thus injuries
ensue. Many reports have addressed this issue, but
the results are conflicting: the hearing loss may be of
sensorineural, conductive, or mixed type; damage ei-
ther occurs immediately or is delayed; in some, hear-
ing improves, in others, there is transient conductive
loss or progressive sensorineural hearing loss (SNHL)
develops. In this paper, we report a study, conducted
over more than 5 years, that aimed to elucidate the
long-term effect of radiation on hearing.
PATIENTS AND METHODS
Patients
Five hundred consecutive patients with newly diag-
nosed NPC were treated in the Department of
Otolaryngology, Kaohsiung Medical University
Hospital, from July 1990 to June 1999. Hearing ability
before and at regular intervals after treatment was
© 2003 Elsevier. All rights reserved.
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serially assessed. For patients with locally advanced
disease, pre-irradiation chemotherapy with cisplatin
120 mg and 5-fluorouracil 1,000 mg was administered
for one or two courses, depending on response and
tolerance. Only patients satisfying the following four
criteria were enrolled in the study: at least 3 months of
audiologic follow-up after completion of RT; no direct
tumor invasion of the middle or inner ear apparatus;
no concurrent chronic ear disease other than otitis
media with effusion (OME) related to NPC (if only one
ear was diseased, the other normal ear was still
analyzable); and no significant SNHL before RT (i.e.
before treatment, bone conduction [BC] hearing thresh-
old was ≤ 50 dB at four frequencies — 0.5 kHz, 1 kHz,
2 kHz, 4 kHz). Finally, patients with persistent or
recurrent disease after one course of RT were excluded
from the study, but patients with neck lymph node
recurrence treated using neck dissection alone were
not excluded unless another relapse was also
documented.
Auditory assessment
At diagnosis and before irradiation, all patients un-
derwent a thorough physical examination by a spe-
cialist in otolaryngology, and baseline pure tone au-
diogram (GSI 10 and GSI 61, Grason-Stadler, Inc.,
Madison, WI, USA) and impedance audiometry
(Amplaid 775 and GSI Tympstar, Grason-Stadler, Inc.,
Madison, WI, USA) were obtained. Post-RT audiologic
assessment using pure tone audiogram and imped-
ance audiometry was carried out again in the third
month after completion of RT and at yearly intervals
thereafter. In order to measure the persistent effect of
irradiation on the auditory apparatus, BC thresholds
were chosen to reflect the cochlear reserve. BC threshold
at 4 kHz was selected to represent high frequencies
and average pure tone (APT), an average of threshold
BC levels at 0.5 kHz, 1 kHz, and 2 kHz, was chosen to
reflect the threshold in the speech range. Because of
the limitation of poor audiometric gain in all BC meas-
urements > 70 dB, a BC threshold > 70 dB is difficult to
measure accurately. For ears with a BC threshold > 70
dB and no clinical evidence of middle ear disease or
anticipated air-bone gap, the measured air conduction
(AC) threshold was used to replace the BC threshold.
Each ear was considered as an independent case.
Compared to values before RT, a post-RT BC change
≥ 10 dB was defined as a significant change. Severe
hearing loss was defined as a 30 dB increase in BC
threshold. No age adjustment was made on the as-
sumption that age would have no significant effect on
hearing during the follow-up period. The proportions
of ears with threshold deterioration at 4 kHz and APT
were compared sequentially at regular intervals until
the last follow-up. The influence of age, post-RT OME,
chemotherapy, and pre-RT hearing status on changes
in BC thresholds were also assessed.
Radiotherapy techniques
All patients received a full course of RT, which ex-
tended over 5.5–7 weeks. Irradiation was given prima-
rily with 6 MV photons by linear accelerator using a
three-field technique, one anterior facial and two lat-
eral opposing facial fields. For patients with upper
cervical lymph node or extensive local invasion, two
lateral opposing faciocervical fields were given, fol-
lowed by the three-field technique. The dose of each
fraction was between 1.8 and 2 Gy, five times a week,
with a total dose of approximately 68–74 Gy. The radia-
tion dose to the inner ear was approximately 70 Gy.
Statistical methods
Data were analyzed using the SPSS statistical package,
version 10.0 (SPSS Inc., Chicago, IL, USA). Chi-squared
test with Yale’s correction was used to determine the
correlation between potential predisposing factors and
the threshold changes at 4 kHz and APT. The paired t-
test was used to evaluate the serial changes in hearing
in each ear.
RESULTS
A total of 150 patients (males: 99, females: 51) with a
mean age of 48.2 years (range, 12–77 years) completed
the study. As each ear was treated as an independent
case, 261 ears were entered in the analysis. The mean
audiologic follow-up after completion of RT was 43.8
months (range, 3–135 months).
A total of 90 ears had OME, 51 ears before RT (of
which 29 resolved after RT) and 39 ears after RT. Post-
RT OME occurred a mean of 9.1 months after RT
(range, 1–100 months).
The pre- and post-RT sensorineural hearing status
at speech and high frequencies are summarized in
Tables 1 and 2. At initial assessment, 11.9% of all ears
had a BC threshold of ≥ 30 dB at speech frequency,
while the corresponding figure at high frequency was
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42.1%. After RT, the percentages of ears with a BC
threshold ≥ 30 dB increased at both speech (15.2–37%)
and high frequencies (49.7–64.4%). The BC threshold
at high frequency was more affected than that at
speech frequency. At speech frequency, 8.9–28.8% of
ears had ≥ 10 dB loss in BC threshold, while at 4 kHz,
the percentage was 18–34.2%. At speech frequencies,
up to 8.2% of ears had severe SNHL, with an increase
of ≥ 30 dB in threshold from baseline, while up to
16.4% of ears had severe SNHL at high frequency. The
degree of SNHL was greater at high frequency than at
speech frequency, as shown by the greater mean in-
crease in threshold from baseline at each interval of
follow-up (except at 3 months after completion of RT).
The first audiologic follow-up was in the third
month after completion of RT. The difference between
the mean BC threshold at this time and that before RT
was significant at both 4 kHz and APT (paired t-test,
both p < 0.001). The mean loss was 5 dB at APT and 3
dB at 4 kHz. Age was associated with significant
deterioration in post-RT APT (Chi-squared test, p < 0.05)
but not at 4 kHz (Chi-squared test, p > 0.05). Post-RT
OME was also associated with an increased hearing
threshold at APT and 4 kHz (Chi-squared test, both
p < 0.05). However, the use of chemotherapy and the
pre-RT hearing level were not predisposing factors for
post-RT hearing loss at either APT or 4 kHz (Chi-
squared test, all p > 0.05). Deterioration of hearing
Table 1. Hearing status at average pure tone (APT)* during each period of follow-up
Post-RT
Pre-RT
3rd mo 1st yr 2nd yr 3rd yr 4th yr 5th yr > 6 yr
No. of ears in study 261 217 145 133 93 79 38 73
Mean loss in
    BC threshold (dB) 5 4.5 4.6 2.9 –2.4 4.2 12.7
No. of ears with
    ≥ 10 dB BC loss (%) 24 (11) 28 (19.3) 21 (18.1) 14 (16) 7 (8.9) 4 (10.6) 21 (28.8)
No. of ears with
    ≥ 30 dB BC loss (%) 2 (0.9) 2 (1.4) 3 (2.3) 1 (1.3) 2 (1.3) 2 (5.3) 6 (8.2)
No. of ears with
    BC threshold ≥ 30 dB (%) 31 (11.9) 44 (20.3) 26 (17.9) 26 (19.5) 22 (23.7) 12 (15.2) 9 (23.7) 27 (37)
*APT = average of bone conduction thresholds at 0.5 kHz, 1 kHz, and 2 kHz. BC = bone conduction; RT = radiotherapy.
Table 2. Hearing status at 4 kHz during each period of follow-up
Post-RT
Pre-RT
3rd mo 1st yr 2nd yr 3rd yr 4th yr 5th yr > 6 yr
No. of ears in study 261 217 145 133 93 79 38 73
Mean loss in
   BC threshold (dB) 3 5 5.5 7.5 5 9.7 15.5
No. of ears with
   ≥ 10 dB BC loss (%) 39 (18) 39 (26.9) 34 (25.6) 26 (28) 18 (22.8) 13 (34.2) 18 (24.7)
No. of ears with
   ≥ 30 dB BC loss (%) 2 (0.9) 4 (2.8) 6 (4.5) 10 (10.8) – 3 (7.9) 12 (16.4)
No. of ears with
   BC threshold ≥ 30 dB (%) 110 (42.1) 117 (53.9) 72 (49.7) 71 (53.4) 57 (61.3) 42 (53.2) 22 (58) 47 (64.4)
BC = bone conduction; RT = radiotherapy.
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thresholds at APT and 4 kHz seemed to progress
during the follow-up period (Figures 1 and 2).
DISCUSSION
The middle and inner ear are inevitably included in
the radiation field when treating patients with head
and neck malignancies, including NPC. A substantial
number of papers have focused on the treatment and
outcome of OME during or after RT, most of which
were related to radiation-induced E-tube dysfunction.
However, few focus on the potential role of radiation
in the development of persistent SNHL, which may be
more frustrating for patients as it is chronic and often
progressive.
Previous studies reported conflicting results for
incidence, time of onset, type, and severity of hearing
loss. The reported incidence of post-RT SNHL varies
from 0 to 50% [3–6]. Histologic examination of the
temporal bone after RT has demonstrated various
anatomic changes, such as necrosis of the ossicles,
destruction of the organ of corti or outer hair cells,
degenerated stria vascularis, and osteoradionecrosis
of the temporal bone [7]. In contrast, another investi-
gation was unable to find any damage at all [8], reflect-
ing the diversity of individual radiosensitivity.
In view of the possible adverse effects of radiation
on hearing, we conducted a long-term study to eluci-
date changes in hearing after irradiation. In order to
overcome potential sources of discrepancy, such as
different diseases, various treatment modalities, and
variations in radiation dose, only patients with NPC
treated with fairly uniform doses were enrolled for
analysis. In addition, adjuvant chemotherapy provided
the opportunity to study the effect of combined
cisplatin and radiation on SNHL. In this long-term
study, the baseline audiogram and clinical examination
together formed the basis for evaluation of hearing
changes after radiation. All patients were serially
followed using audiograms at regular intervals after
treatment and were assessed by an ENT specialist for
hearing deterioration or otologic symptoms. The pa-
tients in this study had a median follow-up of 36
months after radiation. Sixty-four ears (24.5%) had
audiologic follow-up for more than 5 years.
Hearing in the high-frequency range is known to be
more vulnerable to various harmful events, such as
noise, ototoxic drugs, chemotherapy, and radiation.
Frequencies that are functionally important for the
intelligibility of speech are those in the low-frequency
range, i.e. the speech range which was defined as a BC
threshold at APT (average of levels at 0.5 kHz, 1 kHz,
and 2 kHz) in the present study. On the other hand, the
ability to perceive high frequencies is essential for
speech discrimination. The audiograms analyzed in
this paper were divided into two portions: APT BC
level and 4 kHz BC level.
At all intervals of follow-up, more ears had thresh-
old deterioration at 4 kHz than at APT, and the degree
of hearing threshold change was greater at 4 kHz
(except at 3 months). This is consistent with previous
reports [4,7,9]. The difference in the incidence and
degree of hearing deterioration between high and
speech frequencies can be explained by the anatomy of
the cochlea. Tonotopically, the outer hair cells in the
basal turn of the cochlea are responsible for transduc-
tion of higher frequency sound, while lower frequency
sounds are transduced by hair cells situated in the
apex. In the basal turn of the cochlea, the outer hair
cells are arranged in three regular rows, compared to
four irregular rows in the apex. Thus, higher frequency
sounds are represented by a smaller number of cells in
Figure 1. Percentage of ears with ≥ 10 dB loss at average pure
tone (APT) and 4 kHz during follow-up. APT = average of bone
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Figure 2. Percentage of ears with ≥ 30 dB loss at average pure tone
(APT) and 4 kHz during follow-up. APT = average of bone
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the basal turn. As a result, even a less severe injury
may lead to an insufficient number of surviving outer
hair cells in the basal turn, and clinically significant
hearing loss may occur. This is a possible explanation
of why high-pitched hearing is more vulnerable to all
sorts of injuries [5].
Our patients’ mean pre-RT BC thresholds were
19.5 dB at APT and 28.9 dB at 4 kHz. According to the
formula proposed by Robinson and Sutton to calculate
median thresholds at different ages [10], our patients
represented a population with no or only a mild de-
gree of hearing loss at the age of 48 years. Our patients
were considered to be as vulnerable to age-related
hearing loss as the general population. According to
the formula, the expected age-related threshold shift
in the fifth year should be in the range of 1.4 to 2.0 dB
for APT and 3.4 to 5.8 dB for 4 kHz. Therefore, choos-
ing at least a 10 dB loss as a criterion in our subjects
over the 5-year period of follow-up ensured that the
results did not reflect age-related degeneration.
The first audiologic follow-up was in the third
month after RT and the adverse effects of radiation
were already apparent at both APT and 4 kHz. The
mean loss was 5 dB at APT and 3 dB at 4 kHz. There
was a hearing loss of ≥ 10 dB in 11% of ears at APT and
18% of ears at 4 kHz. The changes over such a short
period of time were more likely to be related to the
effect of radiation than the result of age-related
degeneration. Patients with a 10 dB loss in hearing
may not notice it in their daily life, but an increase of
≥ 30 dB in the hearing threshold may result in subjec-
tive hearing loss and patients may have difficulty in
daily communication, especially those patients with a
marginal hearing reserve before RT. However, when
ears with ≥ 30 dB hearing loss were analyzed separately,
no specific factor was found to be related to such a
change. The intrinsic radiosensitivity of the tissue
may contribute to part of the change. Ears in patients
over 50 years old were more likely to have ≥ 10 dB loss
at APT when assessed at each interval after comple-
tion of radiation (except at 3 years). This is probably
because pre-existing degenerative changes in these
ears make them more vulnerable to radiation injury.
However, we did not find proof of this association at
4 kHz. A few researchers reached a similar conclusion
to ours [6,11], but Grau et al reported no significant
correlation between patient age and post-RT SNHL
[12]. The reason for these different findings needs
further elucidation.
During the follow-up period, some patients had
transient and reversible SNHL. Patients in this group
had some characteristics in common: SNHL was mainly
not severe and most patients did not have post-RT
OME. The temporary increase in BC thresholds prob-
ably resulted from some middle ear pathology, such
as ossicular chain defects or stapedial mass loading
[13].
Although our analysis revealed that pre-RT hear-
ing level was not associated with change in hearing
thresholds after irradiation, the pre-RT audiologic
evaluation was still necessary, especially for patients
with a marginal hearing reserve. While hearing loss
may remain subclinical when the hearing threshold is
increased from 0 to 30 dB, a loss from 30 to 60 dB may
cause subjective hearing loss and result in the need for
hearing rehabilitation. This supports the regular use
of audiologic evaluation for patients who receive po-
tentially ototoxic therapeutic modalities, and patients
should also be informed of the risk of developing
SNHL. When pre-existing hearing deficits are
identified, radiologists can choose less ototoxic
treatments, either by modifying the radiation tech-
nique or by substituting cisplatin with less ototoxic
drugs such as carboplatin.
The chemotherapeutic regimen in the study con-
tained cisplatin, which is a notoriously cochleotoxic
drug. The ototoxic effect of cisplatin is dose-related,
with a plateau phenomenon at doses of > 600 mg/m2
[14]. The doses of cisplatin used in our patients were
relatively low (160–240 mg), and this may be why
chemotherapy did not predispose to the development
of SNHL during the follow-up period.
An association between the presence of post-RT
OME and SNHL has been observed [6]; we confirmed
this finding in our analysis. Post-RT OME is consi-
dered to be a result of E-tube dysfunction after irradia-
tion and it plays a major part in conduction hearing
loss after RT. In our opinion, edema, hyperemia, and
desquamation of the mucosa of the middle ear after
irradiation do not cause irreversible SNHL, but instead,
we believe that the presence of post-RT OME is evi-
dence of radiation complications and is a potential
cause of damage in the inner ear and development of
persistent SNHL.
SNHL, at APT and 4 kHz, started as early as after
RT for NPC in our patients, and it seemed to progress
during long-term follow-up (Figures 1 and 2). For
patients with moderate pre-RT hearing disability, any
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further deterioration may cause severe impairment in
their daily communication and may require audiologic
rehabilitation. Thanks to advances in imaging
techniques, we can now define the extent of lesions
more precisely. Shielding the temporal bone or part of
it may be possible in some patients with limited disease,
but for patients whose temporal bone needs to be
included in the irradiation field, the potential risk of
hearing loss should be explained. Hearing should be
monitored at regular intervals so that hearing reha-
bilitation can be started as soon as significant hearing
disability arises.
REFERENCES
1. Moretti JA. Sensorineural hearing loss following radiotherapy
to the nasopharynx. Laryngoscope 1976;86:598–602.
2. Sataloff RT, Rosen DC. Effects of cranial irradiation on hear-
ing acuity: a review of the literature. Am J Otol 1994;15:772–80.
3. Low WK, Fong KW. Hearing disability before and after radio-
therapy for nasopharyngeal carcinoma. J Laryngol Otol 1994;
110:121–3.
4. Anteunis LJC, Hendriks JJT, Manni JJ. A prospective longitu-
dinal study on radiation-induced hearing loss. Am J Surg 1994;
168:408–11.
5. Lau SK, Wei WI, Sham JST, et al. Early changes of auditory
brain stem evoked response after radiotherapy for nasopha-
ryngeal carcinoma – a prospective study. J Laryngol Otol 1992;
106:887–92.
6. Kwong DLW, Wei WI, Sham JST, et al. Sensorineural hearing
loss in patients treated for nasopharyngeal carcinoma: a pro-
spective study of the effect of radiation and cisplatin treatment.
Int J Radiat Oncol Biol Phys 1996;36:281–9.
7. Borsanyi SJ, Blanchard CL. Ionizing radiation and the ear.
JAMA 1962;181:958–61.
8. Gibb AG, Loh HS. The role of radiation in delayed
hearing loss in nasopharyngeal carcinoma. J Laryngol
Otol 2000;114:139–44.
9. Schot LJ, Hilgers FJM, Keus RB, et al. Late effect of radio-
therapy on hearing. Eur Arch Otorhinolaryngol 1992;249:305–8.
10. Robinson DW, Sutton GJ. Age effect in hearing – a comparative
analysis of published threshold data. Audiology 1979;18:320–34.
11. Ho WK, Wei WI, Kwong DLK, et al. Long-term sensorineural
hearing deficit following radiotherapy in patients suffering
from nasopharyngeal carcinoma: a prospective study. Head
Neck 1999;21:547–53.
12. Grau C, Møller K, Overgaard M, et al. Sensorineural hearing
loss in patients treated with irradiation for nasopharyngeal
carcinoma. Int J Radiat Oncol Biol Phys 1991;21:723–8.
13. Tokimoto T, Kanagawa K. Effects of x-ray irradiation on hearing
in guinea pigs. Acta Otolaryngol (Stockh) 1985;100:266–72.
14. Skinner R, Pearson ADJ, Amineddine HA, et al. Ototoxicity of
cisplatinum in children and adolescents. Br J Cancer 1990;61:
927–31.
